News | Page 81 | Englander Institute for Precision Medicine

Vaccine Improves Outcomes in Lynch Syndrome Model

July 29, 2021

Cancer Vaccine Improves Outcomes in Lynch Syndrome Model

A new strategy for developing vaccines against cancer showed promise in a proof-of-concept study led by scientists at Weill Cornell Medicine, NewYork-Presbyterian and Heidelberg University Hospital. The preclinical results could eventually lead to vaccines that cause the immune system to target cancers early in their development, preventing the disease from becoming established.

The ...

Photo credit: Journal of Clinical Oncology

Trial Shows Cell Therapy May Prevent Infections in Patients

July 16, 2021

Treatment with a ready-made preparation of human immune cells helps prevent infections in people whose immune systems are temporarily weakened by leukemia treatment, according to a phase 2 clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian. Infections are a significant problem in patients undergoing chemotherapy for cancer.

The cell preparation, known as romyelocel-L, consists of immature, human-derived immune cells that work to replenish white blood...

July 2021 EIPM Director’s Memo

July 12, 2021

Dear Members of the Englander Institute,

June was a very busy and successful month for all of us at the Englander Institute. Our work was a major focus within the launch of WCM’s “We’re Changing Medicine,” campaign, including the critically important work of our colleagues Drs. Monica Guzman and ...